JP2018527340A - アリール置換ジヒドロキノリノン、その調製及び医薬品としてのその使用 - Google Patents
アリール置換ジヒドロキノリノン、その調製及び医薬品としてのその使用 Download PDFInfo
- Publication number
- JP2018527340A JP2018527340A JP2018506998A JP2018506998A JP2018527340A JP 2018527340 A JP2018527340 A JP 2018527340A JP 2018506998 A JP2018506998 A JP 2018506998A JP 2018506998 A JP2018506998 A JP 2018506998A JP 2018527340 A JP2018527340 A JP 2018527340A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cancer
- mmol
- compound
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *c(c(*)c1*)c(*)c(*C2)c1N(*)C2=O Chemical compound *c(c(*)c1*)c(*)c(*C2)c1N(*)C2=O 0.000 description 6
- YWPJLDIAZYVZTB-UHFFFAOYSA-N Oc(cc(cc1CC2)Br)c1NC2=O Chemical compound Oc(cc(cc1CC2)Br)c1NC2=O YWPJLDIAZYVZTB-UHFFFAOYSA-N 0.000 description 3
- XMZBPYHAUVWSGQ-UHFFFAOYSA-N CC(CC(c(cc1)c(Cc(cc2)ccc2C#N)c(CC2)c1NC2=O)=CN1C)C1=O Chemical compound CC(CC(c(cc1)c(Cc(cc2)ccc2C#N)c(CC2)c1NC2=O)=CN1C)C1=O XMZBPYHAUVWSGQ-UHFFFAOYSA-N 0.000 description 1
- HEOVJSGWXXRDQL-UHFFFAOYSA-N CC(Cc(c(CC1)c2)cc(COC3CCCC3)c2N)C(C)C1=O Chemical compound CC(Cc(c(CC1)c2)cc(COC3CCCC3)c2N)C(C)C1=O HEOVJSGWXXRDQL-UHFFFAOYSA-N 0.000 description 1
- YKDUBDWGMORWNZ-UHFFFAOYSA-N CC(OCc1ncccc1C)=O Chemical compound CC(OCc1ncccc1C)=O YKDUBDWGMORWNZ-UHFFFAOYSA-N 0.000 description 1
- VQPMESRHIUIYFJ-UHFFFAOYSA-N CC(c1ccccn1)Nc(cc(cc1CC2)C(C=C3C)=CN(C)C3=O)c1NC2=O Chemical compound CC(c1ccccn1)Nc(cc(cc1CC2)C(C=C3C)=CN(C)C3=O)c1NC2=O VQPMESRHIUIYFJ-UHFFFAOYSA-N 0.000 description 1
- ZJTKSXUAVVEKPY-UHFFFAOYSA-N CC(c1cccnc1)Oc(cc(cc1CC2)Br)c1NC2=O Chemical compound CC(c1cccnc1)Oc(cc(cc1CC2)Br)c1NC2=O ZJTKSXUAVVEKPY-UHFFFAOYSA-N 0.000 description 1
- YLUSCNMBGNZTNO-UHFFFAOYSA-N CC1=CC(c(cc2)c(Cc3cccc(N)c3)c(CC3)c2NC3=O)=CN(C)C1=O Chemical compound CC1=CC(c(cc2)c(Cc3cccc(N)c3)c(CC3)c2NC3=O)=CN(C)C1=O YLUSCNMBGNZTNO-UHFFFAOYSA-N 0.000 description 1
- NJQXAEGADHOZSQ-UHFFFAOYSA-N CC1=CC(c(cc2)c(Cc3ccccn3)c(CC3)c2NC3=O)=CN(C)C1=O Chemical compound CC1=CC(c(cc2)c(Cc3ccccn3)c(CC3)c2NC3=O)=CN(C)C1=O NJQXAEGADHOZSQ-UHFFFAOYSA-N 0.000 description 1
- FKEZNRMWEHHVMC-UHFFFAOYSA-N CC1=CC(c(cc2)c(Cc3cccnc3)c(CC3)c2NC3=O)=CN(C)C1=O Chemical compound CC1=CC(c(cc2)c(Cc3cccnc3)c(CC3)c2NC3=O)=CN(C)C1=O FKEZNRMWEHHVMC-UHFFFAOYSA-N 0.000 description 1
- GJIWAODVOVRCIZ-UHFFFAOYSA-N CC1=CC(c(cc2CC3)cc(CNC4CCCCC4)c2NC3=O)=CN(C)C1=O Chemical compound CC1=CC(c(cc2CC3)cc(CNC4CCCCC4)c2NC3=O)=CN(C)C1=O GJIWAODVOVRCIZ-UHFFFAOYSA-N 0.000 description 1
- QMOVGPAFKWTLLR-UHFFFAOYSA-N CC1=CC(c(cc2CC3)cc(N)c2NC3=O)=CN(C)C1=O Chemical compound CC1=CC(c(cc2CC3)cc(N)c2NC3=O)=CN(C)C1=O QMOVGPAFKWTLLR-UHFFFAOYSA-N 0.000 description 1
- JEHZLHJHGHNPAX-UHFFFAOYSA-N CC1=CC(c(cc2CC3)cc(NC4CCOCC4)c2NC3=O)=CN(C)C1=O Chemical compound CC1=CC(c(cc2CC3)cc(NC4CCOCC4)c2NC3=O)=CN(C)C1=O JEHZLHJHGHNPAX-UHFFFAOYSA-N 0.000 description 1
- KGKLJQQYYZQCDH-UHFFFAOYSA-N CC1=CC(c(cc2CC3)cc(OCc4cnccc4)c2NC3=O)=CN(C)C1=O Chemical compound CC1=CC(c(cc2CC3)cc(OCc4cnccc4)c2NC3=O)=CN(C)C1=O KGKLJQQYYZQCDH-UHFFFAOYSA-N 0.000 description 1
- NYLYMDOWRDKLGR-UHFFFAOYSA-N CC1=CC(c(cc2CC3)cc(Oc4ccccc4)c2NC3=O)=CN(C)C1=O Chemical compound CC1=CC(c(cc2CC3)cc(Oc4ccccc4)c2NC3=O)=CN(C)C1=O NYLYMDOWRDKLGR-UHFFFAOYSA-N 0.000 description 1
- GUCAWRLLFMDZMS-UHFFFAOYSA-N CC1=CC(c2c(Cc3ccccn3)cc(CCC(N3)=O)c3c2)=CN(C)C1=O Chemical compound CC1=CC(c2c(Cc3ccccn3)cc(CCC(N3)=O)c3c2)=CN(C)C1=O GUCAWRLLFMDZMS-UHFFFAOYSA-N 0.000 description 1
- MYHTUECTQKXLQP-ZETCQYMHSA-N CCO[C@@H]1COCCC1 Chemical compound CCO[C@@H]1COCCC1 MYHTUECTQKXLQP-ZETCQYMHSA-N 0.000 description 1
- MYHTUECTQKXLQP-SSDOTTSWSA-N CCO[C@H]1COCCC1 Chemical compound CCO[C@H]1COCCC1 MYHTUECTQKXLQP-SSDOTTSWSA-N 0.000 description 1
- HACIXUFIWAKFLS-ZETCQYMHSA-N COC[C@H]1OCCCC1 Chemical compound COC[C@H]1OCCCC1 HACIXUFIWAKFLS-ZETCQYMHSA-N 0.000 description 1
- KOBPCNIZLKUGLA-UHFFFAOYSA-N COCc(cc1)ncc1F Chemical compound COCc(cc1)ncc1F KOBPCNIZLKUGLA-UHFFFAOYSA-N 0.000 description 1
- MJXPDBFDHSMVNS-ZETCQYMHSA-N C[C@@H](c1ncccc1)NC Chemical compound C[C@@H](c1ncccc1)NC MJXPDBFDHSMVNS-ZETCQYMHSA-N 0.000 description 1
- DFYCSUKTANLTHI-UHFFFAOYSA-N Cc1c(COc(cc(cc2CC3)C(C=C4C)=CN(C)C4=O)c2NC3=O)nccc1 Chemical compound Cc1c(COc(cc(cc2CC3)C(C=C4C)=CN(C)C4=O)c2NC3=O)nccc1 DFYCSUKTANLTHI-UHFFFAOYSA-N 0.000 description 1
- ACDAPUOXXWLLSC-UHFFFAOYSA-N Cc1cccnc1CO Chemical compound Cc1cccnc1CO ACDAPUOXXWLLSC-UHFFFAOYSA-N 0.000 description 1
- ZSAONVGPMHUZDW-UHFFFAOYSA-N Cc1cccnc1COC Chemical compound Cc1cccnc1COC ZSAONVGPMHUZDW-UHFFFAOYSA-N 0.000 description 1
- GIPAMQFKKFURER-GLGOKHISSA-N Cc1cnc(CO[IH]C2CO[C@@H](COI)CC2)cc1 Chemical compound Cc1cnc(CO[IH]C2CO[C@@H](COI)CC2)cc1 GIPAMQFKKFURER-GLGOKHISSA-N 0.000 description 1
- FOJOQBLFRRLVTF-UHFFFAOYSA-N O=C(CC1)Nc(c(Oc2ccccc2)c2)c1cc2Br Chemical compound O=C(CC1)Nc(c(Oc2ccccc2)c2)c1cc2Br FOJOQBLFRRLVTF-UHFFFAOYSA-N 0.000 description 1
- IKOHIWNOKVSKLN-UHFFFAOYSA-N O=C(CC1)Nc(cc2)c1c(Cc1ccccn1)c2Cl Chemical compound O=C(CC1)Nc(cc2)c1c(Cc1ccccn1)c2Cl IKOHIWNOKVSKLN-UHFFFAOYSA-N 0.000 description 1
- FAVFLDZYCFEKRU-UHFFFAOYSA-N O=C(CCc1cc(Br)c2)Nc1c2OC1CCCCC1 Chemical compound O=C(CCc1cc(Br)c2)Nc1c2OC1CCCCC1 FAVFLDZYCFEKRU-UHFFFAOYSA-N 0.000 description 1
- ZFVGIFUMELHDOX-UHFFFAOYSA-N OC(CCc1cc(Br)c2)Nc1c2OCc1cncnc1 Chemical compound OC(CCc1cc(Br)c2)Nc1c2OCc1cncnc1 ZFVGIFUMELHDOX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562203623P | 2015-08-11 | 2015-08-11 | |
| US62/203,623 | 2015-08-11 | ||
| US201662356579P | 2016-06-30 | 2016-06-30 | |
| US62/356,579 | 2016-06-30 | ||
| PCT/CA2016/050943 WO2017024408A1 (en) | 2015-08-11 | 2016-08-11 | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018527340A true JP2018527340A (ja) | 2018-09-20 |
| JP2018527340A5 JP2018527340A5 (enExample) | 2019-09-26 |
Family
ID=57982883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506998A Pending JP2018527340A (ja) | 2015-08-11 | 2016-08-11 | アリール置換ジヒドロキノリノン、その調製及び医薬品としてのその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10501438B2 (enExample) |
| EP (1) | EP3334717B1 (enExample) |
| JP (1) | JP2018527340A (enExample) |
| KR (1) | KR20180039117A (enExample) |
| CN (1) | CN108290856A (enExample) |
| AU (1) | AU2016305513A1 (enExample) |
| CA (1) | CA2994472A1 (enExample) |
| HK (1) | HK1256753A1 (enExample) |
| IL (1) | IL257347A (enExample) |
| MX (1) | MX2018001751A (enExample) |
| WO (1) | WO2017024408A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022523860A (ja) * | 2019-03-11 | 2022-04-26 | コラボレイティブ メディシナル デベロップメント， エルエルシー | フェロトーシス関連障害の処置のための複素芳香族およびヘテロ二環式芳香族誘導体 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020093162A1 (en) * | 2018-11-07 | 2020-05-14 | Neomed Institute | Treatment of bet inhibitor-resistant cancers and other diseases responsive to dual bet and cbp/ep300 inhibition therapy |
| CN112239456B (zh) * | 2020-06-09 | 2021-09-07 | 浙江理工大学 | 一种取代2，3-二氢喹诺酮化合物的制备方法 |
| CN114276333B (zh) * | 2020-09-28 | 2023-05-09 | 中国科学院上海药物研究所 | 二氢喹喔啉类溴结构域二价抑制剂 |
| WO2024222147A1 (zh) * | 2023-04-23 | 2024-10-31 | 信义核新(北京)生物科技有限公司 | 喹诺酮类似物及其用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4785005A (en) * | 1986-06-25 | 1988-11-15 | Rorer Pharmaceutical Corporation | 6-(6-alkylpyridone)-carbostyril compounds and their cardiotonic uses |
| WO2014095774A1 (de) * | 2012-12-20 | 2014-06-26 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische dihydropyridopyrazinone |
| WO2014096965A2 (en) * | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2015004075A1 (de) * | 2013-07-09 | 2015-01-15 | Bayer Pharma Aktiengesellschaft | Modifizierte bet-proteininhibitorische dihydrochinoxalinone und dihydropyridopyrazinone |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4550166A (en) | 1984-05-21 | 1985-10-29 | American Cyanamid Company | (Pyridinyl)-1,2,4-triazolo[4,3-a]pyridines |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| DE4237656A1 (de) | 1992-06-13 | 1993-12-16 | Merck Patent Gmbh | Benzimidazolderivate |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6465484B1 (en) | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
| AU760020B2 (en) | 1998-08-31 | 2003-05-08 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| MY139563A (en) | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| CN1893950A (zh) | 2003-12-18 | 2007-01-10 | 辉瑞产品公司 | 用p38 MAP激酶抑制剂治疗动物急性炎症的方法 |
| BRPI0507653A (pt) | 2004-03-19 | 2007-07-10 | Warner Lambert Co | derivados de imidazopiridina e imidazopiridina formulação farmacêutica compreendendo os mesmos e uso |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| HRP20150642T1 (hr) | 2006-12-22 | 2015-08-14 | Astex Therapeutics Limited | BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| JP5456681B2 (ja) | 2007-10-17 | 2014-04-02 | ノバルティス アーゲー | ＡＬＫ阻害剤として有用なイミダゾ［１，２−ａ］ピリジン誘導体 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| EP2501232A1 (en) | 2009-11-16 | 2012-09-26 | Merck Sharp & Dohme Corp. | Imidazole derivatives and methods of use thereof |
| HRP20150571T1 (xx) | 2010-12-13 | 2015-07-03 | Array Biopharma, Inc. | Supstituirani n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-karboksamidni spojevi kao inhibitori receptora tirozin kinaze tipa iii |
| GB201114103D0 (en) | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| AR091790A1 (es) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
| TR201807207T4 (tr) | 2012-06-11 | 2018-06-21 | Ucb Biopharma Sprl | Tnf-alfa modüle edici benzimidazol bileşikleri. |
| SG11201408324QA (en) | 2012-06-12 | 2015-01-29 | Abbvie Inc | Pyridinone and pyridazinone derivatives |
| ES2660051T3 (es) | 2012-09-28 | 2018-03-20 | Vanderbilt University | Compuestos heterocíclicos condensados como inhibidores selectivos de BMP |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US20140094456A1 (en) | 2012-10-02 | 2014-04-03 | Intermune, Inc. | Anti-fibrotic pyridinones |
| WO2014128655A1 (en) | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors |
| US9695179B2 (en) | 2013-03-14 | 2017-07-04 | Convergene Llc | Methods and compositions for inhibition of bromodomain-containing proteins |
| KR102244719B1 (ko) | 2013-03-15 | 2021-04-26 | 플렉시콘 인코퍼레이티드 | 헤테로시클릭 화합물 및 그의 용도 |
| WO2014152029A2 (en) | 2013-03-15 | 2014-09-25 | Epigenetix, Inc. | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors |
| US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
| WO2015004533A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| PL3010503T3 (pl) | 2013-06-21 | 2020-08-24 | Zenith Epigenetics Ltd. | Nowe bicykliczne inhibitory bromodomen |
| US20150051208A1 (en) | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
| WO2015049629A1 (en) | 2013-10-01 | 2015-04-09 | Piramal Enterprises Limited | Imidazoquinoline compounds as bromodomain inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| US9428514B2 (en) | 2013-12-09 | 2016-08-30 | Abbvie Inc. | Bromodomain inhibitors |
| SG11201604916YA (en) | 2014-01-09 | 2016-07-28 | Orion Corp | Bicyclic heterocyclic derivatives as bromodomain inhibitors |
| JP6525437B2 (ja) | 2014-04-02 | 2019-06-05 | インターミューン， インコーポレイテッド | 抗線維性ピリジノン |
| KR102702503B1 (ko) * | 2014-04-23 | 2024-09-05 | 인사이트 홀딩스 코포레이션 | BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온 |
| WO2016077656A2 (en) | 2014-11-13 | 2016-05-19 | Convergene Llc | Methods and compositions for inhibition of bromodomain and extraterminal proteins |
| US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| WO2016097870A1 (en) | 2014-12-17 | 2016-06-23 | Zenith Epigenetics Corp. | Substituted bicyclic compounds as bromodomain inhibitors |
| US10231953B2 (en) | 2014-12-17 | 2019-03-19 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
| GB201503720D0 (en) | 2015-03-05 | 2015-04-22 | Glaxosmithkline Ip No 2 Ltd | Chemical compound |
| GB201504689D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| US10501459B2 (en) | 2015-10-21 | 2019-12-10 | Neomed Institute | Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors |
-
2016
- 2016-08-11 AU AU2016305513A patent/AU2016305513A1/en not_active Abandoned
- 2016-08-11 US US15/751,800 patent/US10501438B2/en active Active
- 2016-08-11 CN CN201680058648.1A patent/CN108290856A/zh active Pending
- 2016-08-11 EP EP16834368.9A patent/EP3334717B1/en active Active
- 2016-08-11 KR KR1020187006580A patent/KR20180039117A/ko not_active Withdrawn
- 2016-08-11 JP JP2018506998A patent/JP2018527340A/ja active Pending
- 2016-08-11 MX MX2018001751A patent/MX2018001751A/es unknown
- 2016-08-11 HK HK18115833.9A patent/HK1256753A1/zh unknown
- 2016-08-11 CA CA2994472A patent/CA2994472A1/en not_active Abandoned
- 2016-08-11 WO PCT/CA2016/050943 patent/WO2017024408A1/en not_active Ceased
-
2018
- 2018-02-04 IL IL257347A patent/IL257347A/en unknown
-
2019
- 2019-10-28 US US16/665,198 patent/US20200299262A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4785005A (en) * | 1986-06-25 | 1988-11-15 | Rorer Pharmaceutical Corporation | 6-(6-alkylpyridone)-carbostyril compounds and their cardiotonic uses |
| WO2014095774A1 (de) * | 2012-12-20 | 2014-06-26 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische dihydropyridopyrazinone |
| WO2014096965A2 (en) * | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2015004075A1 (de) * | 2013-07-09 | 2015-01-15 | Bayer Pharma Aktiengesellschaft | Modifizierte bet-proteininhibitorische dihydrochinoxalinone und dihydropyridopyrazinone |
Non-Patent Citations (3)
| Title |
|---|
| ACS CHEMICAL BIOLOGY, vol. 9(5), JPN6020024836, 2014, pages 1160 - 1171, ISSN: 0004303783 * |
| ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 53(24), JPN6020024838, 2014, pages 6126 - 6130, ISSN: 0004303784 * |
| CANCER RESEARCH, vol. 73(11), JPN6020024834, 2013, pages 3336 - 3346, ISSN: 0004303782 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022523860A (ja) * | 2019-03-11 | 2022-04-26 | コラボレイティブ メディシナル デベロップメント， エルエルシー | フェロトーシス関連障害の処置のための複素芳香族およびヘテロ二環式芳香族誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3334717A1 (en) | 2018-06-20 |
| AU2016305513A1 (en) | 2018-03-08 |
| CN108290856A (zh) | 2018-07-17 |
| HK1256753A1 (zh) | 2019-10-04 |
| US10501438B2 (en) | 2019-12-10 |
| EP3334717B1 (en) | 2020-07-01 |
| US20200299262A1 (en) | 2020-09-24 |
| US20180230130A1 (en) | 2018-08-16 |
| WO2017024408A1 (en) | 2017-02-16 |
| KR20180039117A (ko) | 2018-04-17 |
| CA2994472A1 (en) | 2017-02-16 |
| IL257347A (en) | 2018-03-29 |
| EP3334717A4 (en) | 2019-02-13 |
| MX2018001751A (es) | 2018-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11981657B2 (en) | Substituted benzimidazoles, their preparation and their use as pharmaceuticals | |
| JP6154004B2 (ja) | ブロモドメイン阻害剤のベンゾ［ｃ］イソオキサゾロアゼピン及びその使用 | |
| JP2016519660A (ja) | ブロモドメイン阻害剤としてのオキサゾロ［５，４−ｃ］キノリン−２−オン化合物 | |
| US10501459B2 (en) | Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors | |
| US20200299262A1 (en) | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals | |
| US10836742B2 (en) | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals | |
| HK1256752B (en) | Substituted benzimidazoles, their preparation and their use as pharmaceuticals | |
| BR112018002547B1 (pt) | Benzimidazóis substituídos, seus usos, e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190813 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190813 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20190919 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200630 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200714 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210224 |